Abstract：
The success of nanomedicine as a new strategy for drug delivery and targeting prompted the interest in developing approaches toward basic and clinical neuroscience. Despite enormous advances on brain research, central nervous system (CNS) disorders remain the world\'s leading cause of disability, in part due to the inability of the majority of drugs to reach the brain parenchyma. Many attempts to use nanomedicines as CNS drug delivery systems (DDS) were made; among the various non-invasive approaches, nanoparticulate carriers and, particularly, polymeric nanoparticles (NPs) seem to be the most interesting strategies. In particular, the ability of poly-lactide-co-glycolide NPs (PLGA-NPs) specifically engineered with a glycopeptide (g7), conferring to NPs\' ability to cross the blood brain barrier (BBB) in rodents at a concentration of up to 10% of the injected dose, was demonstrated in previous studies using different routes of administrations. Most of the evidence on NP uptake mechanisms reported in the literature about intracellular pathways and processes of cell entry is based on in vitro studies. Therefore, beside the particular attention devoted to increasing the knowledge of the rate of in vivo BBB crossing of nanocarriers, the subsequent exocytosis in the brain compartments, their fate and trafficking in the brain surely represent major topics in this field.
摘要：
纳米医学作为药物递送和靶向的新策略的成功促使人们对开发基础和临床神经科学方法的兴趣。尽管大脑研究取得了巨大进展，中枢神经系统（CNS）疾病仍然是世界上主要的残疾原因，部分原因是大多数药物无法到达脑实质。许多尝试使用纳米药物作为CNS药物递送系统（DDS）进行了;在各种非侵入性方法中，纳米颗粒载体和，特别是,聚合物纳米颗粒（NP）似乎是最有趣的策略。特别是,聚丙交酯-共-乙交酯NP（PLGA-NP）的能力与糖肽（g7），赋予NPs以超过注射剂量10%的浓度穿过啮齿类动物血脑屏障（BBB）的能力，在以前的研究中证明了使用不同的给药途径。文献中报道的关于细胞内途径和细胞进入过程的NP摄取机制的大多数证据是基于体外研究。因此,除了特别关注增加纳米载体体内BBB穿越速率的知识外，随后在脑室的胞吐作用，他们的命运和大脑贩运肯定是这一领域的主要议题。
